Information  X 
Enter a valid email address

Medaphor Group PLC (MED)

  Print      Mail a friend       Annual reports

Monday 07 January, 2019

Medaphor Group PLC

Trading Update

RNS Number : 3017M
Medaphor Group PLC
07 January 2019
 

 

7 January 2019 

MedaPhor Group plc

("MedaPhor" or the "Group" or the "Company")

 

Trading update

 

MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company,   announces that Group turnover for the year to 31 December 2018, which was generated entirely by the Group's Simulation Division, is expected to grow by approximately 27% to between £5.3m and £5.4m (2017: £4.2m).  The pre-exceptionals EBITDA loss for the year is expected to be around £3m (2017: Loss, £1.7m). This includes approximately £1.5m of primarily R&D expenses attributable to investment in the Group's Clinical Artificial Intelligence Division which was established with the acquisition of Intelligent Ultrasound Limited ("IUL") on 6 October 2017 (3 months to 31 December 2017, IUL overheads: £0.2m).  Group management, PLC costs and share-based payment charges included in the adjusted loss are expected to be £0.9m (2017: £0.8m).

 

£4.86m net of costs was received in December from the placing and open offer (RNS: 40941, 26 November 2018) and cash at bank at 31 December 2018 was £5.5m (2017: £4.3m).  

 

 

Enquiries:

MedaPhor Group plc 

www.medaphor.com

Stuart Gall, CEO 
Wilson Jennings, CFO

Tel: +44 (0)29 2075 6534 

 

 

Cenkos Securities - Nominated Advisor and broker

Tel:  +44 (0)20 7397 8900 

Giles Balleny / Cameron MacRitchie (Corporate Finance)

 

Michael Johnson / Julian Morse (Sales) 

 

 

 

Walbrook PR 

Tel: +44 (0)20 7933 8780 or [email protected] 

Anna Dunphy / Paul McManus 

Mob: +44 (0)7876 741 001 / Mob: +44 (0)7980 541 893

     

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TSTSSFSUMFUSESF

a d v e r t i s e m e n t